Last reviewed · How we verify
bromfenac ophthalmic solution
Bromfenac ophthalmic solution, marketed by Bausch & Lomb Incorporated, is a postoperative treatment for inflammation and ocular pain following cataract surgery. The drug's key strength lies in its established market presence, supported by a key composition patent that remains in effect until 2028. The primary risk to consider is the potential increase in competition as the patent approaches expiration.
At a glance
| Generic name | bromfenac ophthalmic solution |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Postoperative inflammation and ocular pain after cataract surgery
Common side effects
- Anterior chamber inflammation
- Foreign body sensation
- Eye pain
- Photophobia
- Blurred vision
Key clinical trials
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. (PHASE4)
- Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |